Intranasal lactoferrin enhances α-secretase-dependent amyloid precursor protein processing via the ERK1/2-CREB and HIF-1α pathways in an Alzheimer's disease mouse model

Neuropsychopharmacology

Volumn 42, Issue 13, 2017, Pages 2504-2515

  Guo, Chuang ^a   Yang, Zhao Hui ^a   Zhang, Shuai ^a   Chai, Rui ^a   Xue, Han ^a   Zhang, Yan Hui ^a   Li, Jia Yi ^a   Wang, Zhan You ^a  

^a NORTHEASTERN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; LACTOFERRIN; LIFICIGUAT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; VASCULOTROPIN; CREB1 PROTEIN, MOUSE; HIF1A PROTEIN, MOUSE; LTF PROTEIN, HUMAN; MAPK1 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; SECRETASE;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; COGNITIVE DEFECT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ESCAPE BEHAVIOR; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREACTIVITY; LATENT PERIOD; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPATIAL LEARNING; SYNAPSE; UPREGULATION; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAPK SIGNALING; METABOLISM; PATHOLOGY; PSYCHOLOGY; RANDOMIZATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTOFERRIN; MALE; MAP KINASE SIGNALING SYSTEM; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PRESENILIN-1; RANDOM ALLOCATION;

EID: 85033587544     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2017.8     Document Type: Article

References (50)

1. Abbott A. (2008). Neuroscience: the plaque plan. Nature 456: 161-164.
2. Aisen P, Leibman A. (1972). Lactoferrin and transferrin: a comparative study. Biochim Biophys Acta 257: 314-323.
3. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
4. Arnold RR, Cole MF, McGhee JR. (1977). A bactericidal effect for human lactoferrin. Science 197: 263-265.
5. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al. (2011). Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 71: 7433-7441.
6. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al. (2012). Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 71: 7433-7441.
7. Calsolaro V, Edison P. (2016). Neuroinflammation in Alzheimer's disease: current evidence and future directions. Alzheimers Dement 12: 719-732.
8. Cao G, Zhu J, Zhong Q, Shi C, Dang Y, HanWet al. (2013). Distinct roles of methamphetamine in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and CREB activation in hippocampus and prefrontal cortex. Neuropharmacology 67: 144-154.
9. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. (1991). Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308.
10. Daulatzai MA. (2016). Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats. Am J Neurodegener Dis 5: 102-130.
11. Fillebeen C, Ruchoux MM, Mitchell V, Vincent S, Benaissa M, Pierce A. (2001). Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res 96: 103-113.
12. Fuller S, Steele M, Munch G. (2010). Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles? Mutat Res 690: 40-49.
13. Garcia-Montoya IA, Cendon TS, Arevalo-Gallegos S, Rascon-Cruz Q. (2012). Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta 1820: 226-236.
14. Guo C, Hao LJ, Yang ZH, Chai R, Zhang S, Gu Y, et al. (2016). Deferoxamine-mediated up-regulation of HIF-1alpha prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-Treated mice. Exp Neurol 280: 13-23.
15. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY. (2013). Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34: 562-575.
16. Guo C, Zhang YX, Wang T, Zhong ML, Yang ZH, Hao LJ, et al. (2015). Intranasal deferoxamine attenuates synapse loss via upregulating the P38/HIF-1alpha pathway on the brain of APP/PS1 transgenic mice. Front Aging Neurosci 7: 104.
17. Ikoma-Seki K, Nakamura K, Morishita S, Ono T, Sugiyama K, Nishino H, et al. (2015). Role of LRP1 and ERK and cAMP signaling pathways in lactoferrin-induced lipolysis in mature rat adipocytes. PLoS One 10: e0141378.
18. Iwamaru Y, Shimizu Y, Imamura M, Murayama Y, Endo R, Tagawa Y, et al. (2008). Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation. J Neurochem 107: 636-646.
19. Jiang R, Lopez V, Kelleher SL, Lonnerdal B. (2011). Apo- And holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERKsignaling and cell proliferation in Caco-2 cells. J Cell Physiol 226: 3022-3031.
20. Johnson EE, Wessling-Resnick M. (2012). Iron metabolism and the innate immune response to infection. Microbes Infect 14: 207-216.
21. Kamalinia G, Khodagholi F, Atyabi F, Amini M, Shaerzadeh F, Sharifzadeh M, et al. (2013). Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies. Mol Pharm 10: 4418-4431.
22. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. (1993). Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 142: 1574-1585.
23. Kim J, Lilliehook C, Dudak A, Prox J, Saftig P, Federoff HJ, et al. (2010). Activity-dependent alpha-cleavage of nectin-1 is mediated by a disintegrin and metalloprotease 10 (ADAM10). J Biol Chem 285: 22919-22926.
24. Kontoghiorghes GJ, Kolnagou A, Skiada A, Petrikkos G. (2010). The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin 34: 227-239.
25. Krasnova IN, Chiflikyan M, Justinova Z, McCoy MT, Ladenheim B, Jayanthi S, et al. (2013). CREB phosphorylation regulates striatal transcriptional responses in the self-Administration model of methamphetamine addiction in the rat. Neurobiol Dis 58: 132-143.
26. Kruzel ML, Actor JK, Radak Z, Bacsi A, Saavedra-Molina A, Boldogh I. (2010). Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun 16: 67-79.
27. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. (1999). Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927.
28. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, Hof PR. (1994). The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650: 20-31.
29. Liu L, Zhu J, Zhou L, Wan L. (2016). RACK1 promotes maintenance of morphine-Associated memory via activation of an ERK-CREB dependent pathway in hippocampus. Sci Rep 6: 20183.
30. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. (1993). Evidence for excitoprotective and intraneuronal calciumregulating roles for secreted forms of the beta-Amyloid precursor protein. Neuron 10: 243-254.
31. Mayeur S, Spahis S, Pouliot Y, Levy E. (2015). Lactoferrin, a pleiotropic protein in health and disease. Antioxid Redox Signal 24: 813-836.
32. Orsi N. (2004). The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17: 189-196.
33. Qian ZM, Wang Q. (1998). Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev 27: 257-267.
34. Ran I, Laplante I, Lacaille JC. (2012). CREB-dependent transcriptional control and quantal changes in persistent long-Term potentiation in hippocampal interneurons. J Neurosci 32: 6335-6350.
35. Rousseau E, Michel PP, Hirsch EC. (2013). The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. Mol Pharmacol 84: 888-898.
36. Selkoe DJ. (1989). Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58: 611-612.
37. Selkoe DJ. (2002). Alzheimer's disease is a synaptic failure. Science 298: 789-791.
38. Shukla M, Htoo HH, Wintachai P, Hernandez JF, Dubois C, Postina R, et al. (2015). Melatonin stimulates the nonamyloidogenic processing of betaAPP through the positive transcriptional regulation of ADAM10 and ADAM17. J Pineal Res 58: 151-165.
39. Takase K. (1998). Reactions of denatured proteins with other cellular components to form insoluble aggregates and protection by lactoferrin. FEBS Lett 441: 271-274.
40. Turner PR, O'Connor K, Tate WP, Abraham WC. (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1-32.
41. van de Looij Y, Ginet V, Chatagner A, Toulotte A, Somm E, Huppi PS, et al. (2014). Lactoferrin during lactation protects the immature hypoxic-ischemic rat brain. Ann Clin Transl Neurol 1: 955-967.
42. Vardy ER, Catto AJ, Hooper NM. (2005). Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11: 464-472.
43. Velusamy SK, Poojary R, Ardeshna R, Alabdulmohsen W, Fine DH, Velliyagounder K. (2014). Protective effects of human lactoferrin during Aggregatibacter actinomycetemcomitans-induced bacteremia in lactoferrin-deficient mice. Antimicrob Agents Chemother 58: 397-404.
44. Vincent B, Govitrapong P. (2011). Activation of the alpha-secretase processing of AbetaPP as a therapeutic approach in Alzheimer's disease. J Alzheimers Dis 24(Suppl 2): 75-94.
45. Wan XZ, Li B, Li YC, Yang XL, Zhang W, Zhong L, et al. (2012). Activation of NMDA receptors upregulates a disintegrin and metalloproteinase 10 via a Wnt/MAPK signaling pathway. J Neurosci 32: 3910-3916.
46. Wang J, Bi M, Liu H, Song N, Xie J. (2015). The protective effect of lactoferrin on ventral mesencephalon neurons against MPP+ is not connected with its iron binding ability. Sci Rep 5: 10729.
47. Wang L, Sato H, Zhao S, Tooyama I. (2010). Deposition of lactoferrin in fibrillar-Type senile plaques in the brains of transgenic mouse models of Alzheimer's disease. Neurosci Lett 481: 164-167.
48. Williams P, Sorribas A, Howes MJ. (2011). Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 28: 48-77.
49. Yan D, Chen D, Hawse JR, van Wijnen AJ, Im HJ. (2013). Bovine lactoferricin induces TIMP-3 via the ERK1/2-Sp1 axis in human articular chondrocytes. Gene 517: 12-18.
50. Zakharova ET, Kostevich VA, Sokolov AV, Vasilyev VB. (2012). Human apo-lactoferrin as a physiological mimetic of hypoxia stabilizes hypoxia-inducible factor-1 alpha. Biometals 25: 1247-1259.